Ligand Pharmaceuticals Inc

Latest Results (14.04.2026):

Ligand Pharmaceuticals Inc reported strong fourth quarter of 2025 results, driven primarily by royalty growth. For Q4 2025, total revenues and income were $59.7 million (up from $42.8M a year earlier), royalties were $50.5 million (a 45% increase YoY) and GAAP net income was $44.8 million, or $2.12 per diluted share. Full-year 2025 results were also materially higher (total revenues $268.1M; GAAP net income $124.5M, or $6.13 per diluted share), and the company reaffirmed 2026 guidance for $245–$285M in revenues and adjusted EPS of $8.00–$9.00.

Q4 2025 revenue

Total revenues and income for the fourth quarter of 2025 were $59.7 million versus $42.8 million in Q4 2024, with the increase driven primarily by higher royalty receipts. Captisol sales for the quarter were $7.8 million and contract revenue/income was $1.3 million.

Q4 2025 earnings

GAAP net income for Q4 2025 was $44.8 million, or $2.12 per diluted share (compared with a GAAP loss in Q4 2024). Adjusted net income was $42.7 million, or $2.02 per diluted share. Q4 GAAP results included a $22.1 million gain from short-term investments.

Royalty performance

Royalties were $50.5 million in Q4 2025 (up 45% YoY) and $161.0 million for full-year 2025 (up from $108.8M in 2024, ~48% growth). The royalty increase was primarily attributable to higher sales of partners’ products including Travere’s Filspari and Merck’s Capvaxive and Ohtuvayre (and contributed by Recordati’s Qarziba and Zelsuvmi-related income).

Full-year 2025 results

For the full year, total revenues and income were $268.1 million (2024: $167.1M). GAAP net income was $124.5 million, or $6.13 per diluted share (2024: GAAP loss). Core adjusted net income was $165.1 million, or $8.13 per diluted share, reflecting royalty growth and Zelsuvmi out-license income.

Expenses and one-time items

R&D expenses rose to $81.2 million in 2025 (vs $21.4M in 2024), driven mainly by a $44.3M one-time charge (Castle Creek financing for D‑Fi) and a $17.8M one-time charge (Orchestra BioMed financing). General & administrative was $92.4M for the year. Financial royalty asset impairment was $6.2M for 2025.

Pelthos transaction impact

The Pelthos spin‑out contributed significantly to contract revenue/income in 2025: $24.5M of Zelsuvmi out-license income plus a $28.6M gain on the sale of the Pelthos business were recorded in the year, boosting total contract-related income.

Balance sheet & liquidity

As of December 31, 2025, Ligand held $733.5 million in cash, cash equivalents and short-term investments. Accounts receivable were $59.6M. The balance sheet also shows a long‑term portion of 2030 convertible senior notes of $446.2M (net) as of year‑end.

2026 guidance

Ligand reiterated 2026 guidance: total revenues of $245–$285 million; royalty revenue $200–$225 million; Captisol sales $35–$40 million; contract revenue $10–$20 million; and adjusted earnings per diluted share of $8.00–$9.00.

Recent business catalysts

Notable updates cited in the release include commercialization and regulatory milestones for partner products (e.g., Zelsuvmi partner launch, Travere Filspari strong U.S. sales — $103M in Q4 2025 — and upcoming sNDA/PDUFA dates, Ohtuvayre NDA acceptance in China, positive Phase 3/2 reads for Qtorin rapamycin, and regulatory progress for Tzield/Teizeild).